As signal transducers and transcription factors, signal transducer and activator of transcriptions (STATs) exert a critical role in cell growth, differentiation, and cell death. Their dysregulation that may lead to constitutive activation, no activation, or functional change, is associated with many different cancers. In this review, the contribution of STATs to cancer growth and progression is presented, and then the context in which interferon regulation of STAT activation provides a mechanism for therapeutic intervention for specific cancers is discussed.
Get full access to this article
View all access options for this article.
References
1.
AkiraS. 1999. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells, 17,3:138–146.
2.
AkiraS. 2000. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene, 19,21:2607–2611.
3.
AlasS, BonavidaB. 2001. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res, 61,13:5137–5144.
4.
AlasS, EmmanouilidesC, BonavidaB. 2001. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res, 7,3:709–723.
AroraA, ScholarEM. 2005. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther, 315,3:971–979.
7.
ArredondoJ, ChernyavskyAI, JolkovskyDL, PinkertonKE, GrandoSA. 2006. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J, 20,12:2093–2101.
8.
AzizMH, ManoharanHT, VermaAK. 2007. Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res, 67,3:1385–1394.
9.
BarbieriI, PensaS, PannelliniT, QuaglinoE, MaritanoD, DemariaM, VosterA, TurksonJ, CavalloF, WatsonCJ, ProveroP, MusianiP, PoliV. 2010. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res, 70,6:2558–2567.
10.
BartonBE, KarrasJG, MurphyTF, BartonA, HuangHF. 2004. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther, 3,1:11–20.
11.
BenekliM, BaumannH, WetzlerM. 2009. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol, 27,26:4422–4432.
12.
BenekliM, XiaZ, DonohueKA, FordLA, PixleyLA, BaerMR, BaumannH, WetzlerM. 2002. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood, 99,1:252–257.
13.
BewryNN, NairRR, EmmonsMF, BoulwareD, Pinilla-IbarzJ, HazlehurstLA. 2008. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther, 7,10:3169–3175.
14.
Bronte-TinkewDM, TerebiznikM, FrancoA, AngM, AhnD, MimuroH, SasakawaC, RopeleskiMJ, PeekRMJr., JonesNL. 2009. Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res, 69,2:632–639.
15.
BrunsHA, KaplanMH. 2006. The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol, 57,3:245–253.
16.
BuettnerR, MoraLB, JoveR. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res, 8,4:945–954.
17.
CalòV, MigliavaccaM, BazanV, MacalusoM, BuscemiM, GebbiaN, RussoA. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol, 197,2:157–168.
ChenHL, GabrilovichD, TampéR, GirgisKR, NadafS, CarboneDP. 1996. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet, 13,2:210–213.
20.
ChenX, VinkemeierU, ZhaoY, JeruzalmiD, DarnellJEJr., KuriyanJ. 1998. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell, 93,5:827–839.
21.
CheonH, StarkGR. 2009. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A, 106,23:9373–9378.
22.
ChiuWT, LeeHT, HuangFJ, AldapeKD, YaoJ, SteegPS, ChouCY, LuZ, XieK, HuangS. 2011. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res, 71,14:4932–4943.
23.
ConnettJM, HuntSR, HickersonSM, WuSJ, DohertyGM. 2003. Localization of IFN-gamma-activated Stat1 and IFN regulatory factors 1 and 2 in breast cancer cells. J Interferon Cytokine Res, 23,11:621–630.
24.
CoppolaD, ParikhV, BoulwareD, BlanckG. 2009. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol, 135,9:1287–1291.
25.
CorvinusFM, OrthC, MorigglR, TsarevaSA, WagnerS, PfitznerEB, BausD, KaufmannR, HuberLA, ZatloukalK, BeugH, OhlschlägerP, SchützA, HalbhuberKJ, FriedrichK. 2005. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia, 7,6:545–555.
26.
DasS, RothCP, WassonLM, VishwanathaJK. 2007. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate, 67,14:1550–1564.
27.
DauerDJ, FerraroB, SongL, YuB, MoraL, BuettnerR, EnkemannS, JoveR, HauraEB. 2005. Stat3 regulates genes common to both wound healing and cancer. Oncogene, 24,21:3397–3408.
28.
DiazN, MintonS, CoxC, BowmanT, GritskoT, GarciaR, EweisI, WlochM, LivingstonS, SeijoE, CantorA, LeeJH, BeamCA, SullivanD, JoveR, Muro-CachoCA. 2006. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res, 12,1:20–28.
29.
DingBB, YuJJ, YuRY, MendezLM, ShaknovichR, ZhangY, CattorettiG, YeBH. 2008. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood, 111,3:1515–1523.
30.
EriksenKW, SøndergaardH, WoetmannA, KrejsgaardT, SkakK, GeislerC, WasikMA, OdumN. 2009. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Mol Immunol, 46,5:812–820.
31.
FosseySL, LiaoAT, McCleeseJK, BearMD, LinJ, LiPK, KisseberthWC, LondonCA. 2009. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer, 9:81.
32.
GameroAM, YoungMR, Mentor-MarcelR, BobeG, ScarzelloAJ, WiseJ, ColburnNH. 2010. STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila), 3,4:495–504.
33.
GarciaR, BowmanTL, NiuG, YuH, MintonS, Muro-CachoCA, CoxCE, FalconeR, FaircloughR, ParsonsS, LaudanoA, GazitA, LevitzkiA, KrakerA, JoveR. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene, 20,20:2499–2513.
34.
GrandisJR, DrenningSD, ZengQ, WatkinsSC, MelhemMF, EndoS, JohnsonDE, HuangL, HeY, KimJD. 2000. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A, 97,8:4227–4232.
35.
GrimleyPM, FangH, RuiH, PetricoinEF3rd, RayS, DongF, FieldsKH, HuR, ZoonKC, AudetS, BeelerJ. 1998. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood, 91,8:3017–3027.
36.
GritskoT, WilliamsA, TurksonJ, KanekoS, BowmanT, HuangM, NamS, EweisI, DiazN, SullivanD, YoderS, EnkemannS, EschrichS, LeeJH, BeamCA, ChengJ, MintonS, Muro-CachoCA, JoveR. 2006. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res, 12,1:11–19.
37.
GuL, VogiatziP, PuhrM, DagvadorjA, LutzJ, RyderA, AddyaS, FortinaP, CooperC, LeibyB, DasguptaA, HyslopT, BubendorfL, AlanenK, MirttiT, NevalainenMT. 2010. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer, 17,2:481–493.
38.
GuoC, YangG, KhunK, KongX, LevyD, LeeP, MelamedJ. 2009. Activation of Stat3 in renal tumors. Am J Transl Res, 1,3:283–290.
39.
HarirN, PecquetC, KerenyiM, SonneckK, KovacicB, NygaR, BrevetM, DhenninI, Gouilleux-GruartV, BeugH, ValentP, LassouedK, MorigglR, GouilleuxF. 2007. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood, 109,4:1678–1686.
40.
HoHH, IvashkivLB. 2006. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem, 281,20:14111–14118.
41.
HoltickU, VockerodtM, PinkertD, SchoofN, StürzenhofeckerB, KussebiN, LauberK, WesselborgS, LöfflerD, HornF, TrümperL, KubeD. 2005. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia, 19,6:936–944.
42.
HsiehFC, ChengG, LinJ. 2005. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun, 335,2:292–299.
43.
Humpoliková-AdámkováL, KovaríkJ, DusekL, LauerováL, BoudnýV, FaitV, FojtováM, KrejcíE, KovaríkA. 2009. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. Eur J Cancer, 45,7:1315–1323.
44.
IkedaK, KobayashiM, SekoY, ImaiN, HirakawaM, KawamuraY, SezakiH, HosakaT, AkutaN, SaitohS, SuzukiF, SuzukiY, AraseY, KumadaH. 2010. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Hepatol Res, 40,12:1168–1175.
45.
InamuraK, MatsuzakiY, UematsuN, HondaA, TanakaN, UchidaK. 2005. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. Biochim Biophys Acta, 1745,3:401–410.
46.
JiangLJ, ZhangNN, DingF, LiXY, ChenL, ZhangHX, ZhangW, ChenSJ, WangZG, LiJM, ChenZ, ZhuJ. 2011. RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc Natl Acad Sci U S A, 108,5:1897–1902.
47.
JingN, ShaW, LiY, XiongW, TweardyDJ. 2005. Rational drug design of G-quartet DNA as anti-cancer agents. Curr Pharm Des, 11,22:2841–2854.
48.
KaymazBT, SelviN, GündüzC, AktanC, DalmızrakA, SaydamG, KosovaB. 2012. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann Hematol, 2012[Epub ahead of print].10.1007/s00277-012-1575-2.
49.
KhongT, SharkeyJ, SpencerA. 2008. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica, 93,6:860–869.
50.
KisselevaT, BhattacharyaS, BraunsteinJ, SchindlerCW. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene, 285,1–2:1–24.
51.
KloverPJ, MullerWJ, RobinsonGW, PfeifferRM, YamajiD, HennighausenL. 2010. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia, 12,11:899–905.
52.
KlugeA, DabirS, VlassenbroeckI, EisenbergR, DowlatiA. 2011. Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol, 5,3:256–264.
LeeSO, LouW, QureshiKM, Mehraein-GhomiF, TrumpDL, GaoAC. 2004. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate, 60,4:303–309.
59.
LeibowitzMS, Andrade FilhoPA, FerroneS, FerrisRL. 2011. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother, 60,4:525–535.
60.
LianJP, WordB, TaylorS, HammonsGJ, Lyn-CookBD. 2004. Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res, 24,1:133–137.
61.
LimCP, CaoX. 2006. Structure, function, and regulation of STAT proteins. Mol Biosyst, 2,11:536–550.
62.
LinL, LiuA, PengZ, LinHJ, LiPK, LiC, LinJ. 2011. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res, 71,23:7226–7237.
63.
LiuYP, TanYN, WangZL, ZengL, LuZX, LiLL, LuoW, TangM, CaoY. 2008. Phosphorylation and nuclear translocation of STAT3 regulated by the Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Int J Mol Med, 21,2:153–162.
64.
MaherSG, SheikhF, ScarzelloAJ, Romero-WeaverAL, BakerDP, DonnellyRP, GameroAM. 2008. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther, 7,7:1109–1115.
65.
MalinS, McManusS, BusslingerM. 2010. STAT5 in B cell development and leukemia. Curr Opin Immunol, 22,2:168–176.
66.
MoraLB, BuettnerR, SeigneJ, DiazJ, AhmadN, GarciaR, BowmanT, FalconeR, FaircloughR, CantorA, Muro-CachoC, LivingstonS, KarrasJ, Pow-SangJ, JoveR. 2002. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res, 62,22:6659–6666.
67.
NairRR, TolentinoJH, HazlehurstLA. 2012. Role of STAT3 in Transformation and Drug Resistance in CML. Front Oncol, 2:30.
68.
NiuG, WrightKL, MaY, WrightGM, HuangM, IrbyR, BriggsJ, KarrasJ, CressWD, PardollD, JoveR, ChenJ, YuH. 2005. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol, 25,17:7432–7440.
69.
OzawaY, WilliamsAH, EstesML, MatsushitaN, BoschelliF, JoveR, ListAF. 2008. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)Leuk Res, 32,6:893–903.
70.
PanerGP, SilbermanS, HartmanG, MicetichKC, AranhaGV, AlkanS. 2003. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res, 23,3B:2253–2260.
71.
PedranziniL, LeitchA, BrombergJ. 2004. Stat3 is required for the development of skin cancer. J Clin Invest, 114,5:619–622.
RedellMS, RuizMJ, AlonzoTA, GerbingRB, TweardyDJ. 2011. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood, 117,21:5701–5709.
ScarzelloAJ, Romero-WeaverAL, MaherSG, VeenstraTD, ZhouM, QinA, DonnellyRP, SheikhF, GameroAM. 2007. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol Biol Cell, 18,7:2455–2462.
80.
SchindlerC, PlumleeC. 2008. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol, 19,4:311–318.
81.
SchlessingerK, LevyDE. 2005. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res, 65,13:5828–5834.
82.
ShenH, LentschAB. 2004. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol, 286,4:C840–C847.
83.
ShuklaS, ShishodiaG, MahataS, HedauS, PandeyA, BhambhaniS, BatraS, BasirSF, DasBC, BhartiAC. 2010. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer, 9:282.
84.
SommerVH, ClemmensenOJ, NielsenO, WasikM, LovatoP, BrenderC, EriksenKW, WoetmannA, KaestelCG, NissenMH, RopkeC, SkovS, ØdumN. 2004. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia, 18,7:1288–1295.
85.
SongL, RawalB, NemethJA, HauraEB. 2011. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther, 10,3:481–494.
86.
SunWH, PabonC, AlsayedY, HuangPP, JandeskaS, UddinS, PlataniasLC, RosenST. 1998. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood, 91,2:570–576.
87.
TakedaK, NoguchiK, ShiW, TanakaT, MatsumotoM, YoshidaN, KishimotoT, AkiraS. 1997. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A, 94,8:3801–3804.
88.
TanakaT, SorianoMA, GrusbyMJ. 2005. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity, 22,6:729–736.
89.
TuB, DuL, FanQM, TangZ, TangTT. 2012. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett, 325,1:80–88.
90.
TurksonJ, JoveR. 2000. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19,56:6613–6626.
91.
TurksonJ, KimJS, ZhangS, YuanJ, HuangM, GlennM, HauraE, SebtiS, HamiltonAD, JoveR. 2004. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther, 3,3:261–269.
92.
VitaleG, ZappavignaS, MarraM, DicitoreA, MeschiniS, CondelloM, AranciaG, CastiglioniS, MaroniP, BendinelliP, PiccolettiR, van KoetsveldPM, CavagniniF, BudillonA, AbbruzzeseA, HoflandLJ, CaragliaM. 2012. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv, 30,1:169–184.
WeerasingheP, GarciaGE, ZhuQ, YuanP, FengL, MaoL, JingN. 2007. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol, 31,1:129–136.
95.
WidschwendterA, Tonko-GeymayerS, WelteT, DaxenbichlerG, MarthC, DopplerW. 2002. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res, 8,10:3065–3074.
96.
WilopS, van GemmerenTB, LentjesMH, van EngelandM, HermanJG, BrümmendorfTH, JostE, GalmO. 2011. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics, 6,8:1047–1052.
97.
WormaldS, HiltonDJ. 2004. Inhibitors of cytokine signal transduction. J Biol Chem, 279,2:821–824.
98.
XiS, ZhangQ, DyerKF, LernerEC, SmithgallTE, GoodingWE, KamensJ, GrandisJR. 2003. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem, 278,34:31574–31583.
99.
XiaZ, SaitSN, BaerMR, BarcosM, DonohueKA, LawrenceD, FordLA, BlockAM, BaumannH, WetzlerM. 2001a. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res, 25,6:473–482.
100.
XiaZ, SalzlerRR, KunzDP, BaerMR, KazimL, BaumannH, WetzlerM. 2001b. A novel serine-dependent proteolytic activity is responsible for truncated signal transducer and activator of transcription proteins in acute myeloid leukemia blasts. Cancer Res, 61,4:1747–1753.
101.
XieTX, HuangFJ, AldapeKD, KangSH, LiuM, GershenwaldJE, XieK, SawayaR, HuangS. 2006. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res, 66,6:3188–3196.
102.
XiongH, HongJ, DuW, LinYW, RenLL, WangYC, SuWY, WangJL, CuiY, WangZH, FangJY. 2012. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem, 287,8:5819–5832.
103.
XuG, ZhangC, ZhangJ. 2009. Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. Mol Med Report, 2,5:819–824.
104.
YamadaO, OzakiK, FurukawaT, MachidaM, WangYH, MotojiT, MitsuishiT, AkiyamaM, YamadaH, KawauchiK, MatsuokaR. 2011. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal, 23,7:1119–1127.
105.
YangJ, Chatterjee-KishoreM, StaugaitisSM, NguyenH, SchlessingerK, LevyDE, StarkGR. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res, 65,3:939–947.
106.
YangJ, LiaoX, AgarwalMK, BarnesL, AuronPE, StarkGR. 2007. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev, 21,11:1396–1408.
107.
YangJ, StarkGR. 2008. Roles of unphosphorylated STATs in signaling. Cell Res, 18,4:443–451.
108.
YoneyamaM, KikuchiM, NatsukawaT, ShinobuN, ImaizumiT, MiyagishiM, TairaK, AkiraS, FujitaT. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol, 5,7:730–737.
109.
YoshidaT, HanadaT, TokuhisaT, KosaiK, SataM, KoharaM, YoshimuraA. 2002. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med, 196,5:641–653.
110.
YouM, YuDH, FengGS. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol, 19,3:2416–2424.
111.
YuH, PardollD, JoveR. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 9,11:798–809.
112.
ZammarchiF, de StanchinaE, BournazouE, SupakorndejT, MartiresK, RiedelE, CorbenAD, BrombergJF, CartegniL. 2011. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A, 108,43:17779–17784.
113.
ZhanJF, ChenLH, YuanYW, XieGZ, SunAM, LiuY, ChenZX. 2011. STAT1 promotes radioresistance of CD44(+)/CD24(−/low) cells in breast cancer. Exp Biol Med (Maywood), 236,4:418–422.
114.
ZhangNN, ShenSH, JiangLJ, ZhangW, ZhangHX, SunYP, LiXY, HuangQH, GeBX, ChenSJ, WangZG, ChenZ, ZhuJ. 2008. RIG-I plays a critical role in negatively regulating granulocytic proliferation. Proc Natl Acad Sci U S A, 105,30:10553–10558.
ZhangX, YueP, PageBD, LiT, ZhaoW, NamanjaAT, PaladinoD, ZhaoJ, ChenY, GunningPT, TurksonJ. 2012. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA, 109,24:9623–9628.
117.
ZhouY, WangS, GoblA, ObergK. 2001. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors. Oncology, 60,4:330–338.
118.
ZhuH, WangZ, XuQ, ZhangY, ZhaiY, BaiJ, LiuM, HuiZ, XuN. 2012. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy. Cancer Biol Ther, 13,6:401–407.
119.
ZimmermanMA, RahmanNT, YangD, LahatG, LazarAJ, PollockRE, LevD, LiuK. 2012. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res, 72,18:4724–4732.
